DUBLIN--(BUSINESS WIRE)--The "Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Industry Analysis & Outlook (2017-2026)" report has been added to Research and Markets' offering.
The report "Global NASH Drugs Market: Industry Analysis & Outlook (2017-2026)" analyzes the development of this market, with focus on the US and Europe region. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Genfit SA, Intercept Pharmaceuticals, Inc., Allergan Plc. (Tobira) and Gilead Sciences are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global NASH market along with the study of the regional markets.
Treatment of NASH includes managing and improving the condition of NASH from being worse and is recommended to bring changes in lifestyle and also use of off label drugs to control and manage indications related to NASH. Currently there is no approved drug in the market but is expected to enter the market in 2020. Currently, there are five potential Phase III drugs in the market including Elafibranor, Ocaliva (OCA), Cenicriviroc (CVC), Selonsertib and Aramchol.
The global NASH market is expected to show significant growth after the introduction of therapeutics drugs in 2020. Growth of market will mainly be driven by increasing patient base, rise in obese population, increasing type-2 diabetic population and increasing health expenditure. However, growth of market will also be hindered by absence of effective diagnostics, costly drugs, regulatory challenges and undefined pathogenesis.
Market Dynamics
Growth Drivers
- Rising Patient Base
- Increasing Population with Type-2 Diabetes
- Escalating Obese Population
- Rising Healthcare Expenditure
- Increasing GDP Per Capita
- Vast Unmet Medical Need
Key Trends & Development
- Strong Research & Development Efforts by Companies
- Development of NASH Diagnosis Methods and Biomarkers
Challenges
- Absence of Low-Priced and Effective Diagnostics
- Regulatory Challenges and Undefined Pathogenesis
- Costly NASH Therapeutics
Key Topics Covered:
1. Market Overview
2. Global NASH Market
3. Global NASH Therapeutics Market
4. Regional NASH Market
5. Market Dynamics
6. Competitive Landscape
7. Company Profiles
- Allergan (Tobira)
- Genfit SA
- Gilead Sciences
- Intercept Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/research/qh4zrd/global
